CRISPR-Cas9: Shaping the Future of Gene Editing in Treating Sickle Cell Disease

On February 13, 2024, the EU granted conditional approval for CASGEVY™ (exa-cel), a groundbreaking CRISPR/Cas9 therapy for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients lacking matched stem cell donors. This follows recent approvals by the MHRA and FDA, making CASGEVY™ a pivotal advancement in gene editing for genetic diseases. While CASGEVY™ offers transformative potential, the estimated $2 million cost per patient poses accessibility challenges, especially in high-burden areas like Africa where resources for SCD care are limited.

Please enter your details to get access to the content